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Abstract
Cystic fibrosis-related diabetes affects up to half of cystic fibrosis patients and is associated
with increased mortality and more frequent pulmonary exacerbations. However, it is unclear
to what degree good glycemic control might mitigate these risks and clinical outcomes have
not previously been studied in relation to glucose from the lower airways, the site of infection
and CF disease progression. We initially hypothesized that diabetic cystic fibrosis patients
with glycosylated hemoglobin (HbA1c)> 6.5% have worse pulmonary function, longer and
more frequent exacerbations and also higher sputum glucose levels than patients with
HbA1c 6.5% or cystic fibrosis patients without diabetes. To test this, we analyzed sponta-
neously expectorated sputum samples from 88 cystic fibrosis patients. The median sputum
glucose concentration was 0.70 mM (mean, 4.75 mM; range, 0-64.6 mM). Sputum glucose
was not correlated with age, sex, body mass index, diabetes diagnosis, glycemic control, ex-
acerbation frequency or length, or pulmonary function. Surprisingly, sputum glucose was
highest in subjects with normal glucose tolerance, suggesting the dynamics of glycemic con-
trol, sputum glucose and pulmonary infections are more complex than previously thought.
Two-year mean HbA1c was positively correlated with the length of exacerbation admission
(p< 0.01), and negatively correlated with measures of pulmonary function (p< 0.01). While
total number of hospitalizations for exacerbations were not significantly different, subjects
with an HbA1c> 6.5% were hospitalized on average 6 days longer than those with
HbA1c 6.5% (p< 0.01). Current clinical care guidelines for cystic fibrosis-related diabetes
target HbA1c 7% to limit long-term microvascular damage, but more stringent glycemic
control (HbA1c 6.5%) may further reduce the short-term pulmonary complications.
Introduction
Proper blood glucose management of cystic fibrosis-related diabetes (CFRD) adds a substantial
burden to patients who already spend hours every day managing pulmonary, GI, and other
complications of cystic fibrosis (CF). Microvascular complications of CFRD typically arise
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more than 10 years after diagnosis [1], when CF patients are approaching their median life ex-
pectancy in their mid-30s [2]. In addition to potential long-term complications, evidence sug-
gests that CFRD reduces pulmonary function [3] and increases the frequency and likelihood of
treatment failure [4, 5] in pulmonary exacerbations (PEx), the primary cause of mortality in
CF [6, 7]. It is unclear by what mechanism CFRD negatively impacts pulmonary health and if
stringent glycemic control would reduce these effects. It is frequently hypothesized that
CFRD increases sputum glucose (SG), which could support airway pathogens and contribute
to PEx [8, 9].
Work by Brennan et al. [10] and Baker et al. [11] indicates that hyperglycemia causes an in-
crease in glucose concentrations in nasal secretions and breath condensates of CFRD patients,
and these have been used as proxies for airway glucose in lower airways. However, no studies
have examined the effects of sputum glucose on pulmonary health, even though sputum directly
represents the conditions of the small airways frequently infected and damaged in CF. To better
characterize the environment of the lower airways in CF, we measured SG from adult and pedi-
atric CF patients at baseline and during PEx. We also conducted a two-year chart review to pro-
vide context for SG measurements and to investigate if stringent glycemic control in CFRD was
associated with better pulmonary health. We found that while sputum glucose was quite low
and not associated with CFRD, average glycosylated hemoglobin (HbA1c) 6.5% was associat-
ed with improved health outcomes for CFRD patients.
Methods
Ethics statement: patient recruitment and chart review
CF patients from Children’s Hospital Los Angeles and Keck Hospital of USC were consented
and assented in writing in accordance with the Institutional Review Board at Children’s Hospi-
tal Los Angeles and the University of Southern California Health Science Institutional Review
Board, IRB# CCI-13–00211 and HS-14–00068, respectively. The entire study was reviewed and
approved by the Institutional Review Board at Children’s Hospital Los Angeles. Informed con-
sent from a parent or legal guardian was obtained for patients< 18 years old, and assent of pa-
tients 13–18 years old was also obtained. Inclusion criteria were 4 years old, CF diagnosis,
and the ability to spontaneously produce sputum. A retrospective chart review of subjects’
health records from January 2012—December 2013 was performed to obtain age, ethnicity
(self-reported as white, Hispanic, black or other), body mass index (BMI), history of PEx,
CFRD status, and sputum culture and blood test results. Oral glucose tolerance tests deter-
mined glucose tolerance according to Cystic Fibrosis Foundation and American Diabetes Asso-
ciation guidelines [12]. For data analysis, CFRD with and without fasting hyperglycemia were
considered as one group. BMI is used as an indicator of nutrition in CF patients and this was
considered in the analyses. We did not have enough information to control for socioeconomic
status or environmental exposures.
Sputum acquisition and preparation
Sputum samples were processed as described by Hunter et al. [13]. Briefly, samples were flash-
frozen in liquid nitrogen immediately upon expectoration and stored at -80°C. Upon thawing,
samples were briefly centrifuged at 8,000 x g, 1 min to separate sputum from saliva. The
mass of sputum samples was measured, and an equal mass of 50 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) buffer was added. This was homogenized by repeat-
edly passing through a #16 needle, then centrifuged at 8,000 x g, 10 minutes. The supernatant
was filtered on a 0.2 μm-pore-size column at 10,000 x g, 20 minutes.
SputumGlucose in CFRD
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Sputum glucose measurement
Filtered sputum supernatant was tested with a colorimetric glucose hexokinase assay (Sigma-
Aldrich, GAHK20) calibrated for glucose concentrations 0–22.2 mM on a 96-well plate reader
(BioTek). Samples were measured in triplicate and the average compared to a standard glucose
curve on each plate. Resulting values were doubled to account for the HEPES dilution described
in section 2.2. Samples that initially tested above the calibrated range of the assay and from
which sufficient supernatant remained were diluted five-fold with Millipore water and re-tested.
Statistical analysis
Calculations of mean and median, standard deviation and error, t-tests and regression analyses
were performed using JMP Pro 11. P-values< 0.05 were considered statistically significant.
Results
Study participant demographics
Eighty-eight subjects with CF were enrolled. Their demographic information is described in
Table 1 and also available in the Supplementary Information Data Tables (S1 Dataset and
S2 Dataset). Most of the subjects were white or Hispanic (84%), and 45% had abnormal glucose
tolerance. On average, the subjects were young adults of BMI within one SD of CFF recom-
mendations [14]. Mean forced expiratory volume in one second (FEV1) score is consistent
with moderate disease severity.
Sputum glucose distribution
To characterize SG, we tested sputum samples from the subject cohort described in Table 1,
with multiple samples from 21 subjects. Sputum glucose was< 0.01 mM in 34% and<1.0 mM
in 55% of sputum samples (40 and 64, respectively, out of 117 samples, see Fig. 1). The distri-
bution of SG was highly skewed: the median concentration was 0.7 mM (IQR, 0–3.5 mM) ver-
sus the mean of 4.75 mM (SD 11.4 mM). There were no clear trends in SG over time from
individual patients who provided multiple samples.
SG and clinical parameters
To determine if SG values were correlated with glucose tolerance, we compared data from our
chart review with SG values. Two-year mean HbA1c was highest in subjects with CFRD, as
Table 1. Study participant demographic information, n = 88.
Characteristic
Age (years), mean (SD) 24.3 (10.0)




Black / other 4 (5)
BMI, male (kg/m2), mean (SD) 21.2 (3.3)
BMI, female (kg/m2), mean (SD) 20.8 (3.7)
FEV1 (% predicted), mean (SD) 62.7 (26.6)
FEF25–75 (% predicted), mean (SD) 43.4 (30.7)
doi:10.1371/journal.pone.0119938.t001
SputumGlucose in CFRD
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expected (see Fig. 2). However, SG was not increased in CFRD, but rather was significantly
higher in those with normal glucose tolerance (NGT). Further bivariate analyses with other
clinical values did not show significant correlations (see Table 2). There was a statistically sig-
nificant positive correlation between SG and forced expiratory flow in the 25–75% of exhala-
tion (FEF 25–75%), but given the nearly flat trendline and low R2, this is likely not
clinically significant.
CFRD and pulmonary health
Because SG was not correlated with glucose tolerance, we analyzed PEx hospital admission his-
tory over the prior two years to determine if CFRD subjects in this cohort had clinically signifi-
cant pulmonary health differences compared to CF subjects without diabetes.
Fig 1. Distribution of sputum glucose concentration in 117 samples. Sputum glucose (SG) was much
lower than previously reported, with 34% reading< 0.01 mM, and 55% of samples reading< 1.0 mM. The
distribution of SG was highly skewed: the median concentration was 0.7 mM (IQR, 0–3.5 mM) versus the
mean of 4.75 mM (SD 11.4 mM).
doi:10.1371/journal.pone.0119938.g001
Fig 2. Comparisons of HbA1c and SG by glucose tolerance. CFRD subjects had significantly higher HbA1c than subjects with impaired (IGT) or normal
glucose tolerance (NGT, left panel), while NGT subjects had significantly higher average sputum glucose than IGT or CFRD subjects (right panel). Diamonds
are centered on each category’s mean and the vertical distance represents the 95% confidence interval.
doi:10.1371/journal.pone.0119938.g002
SputumGlucose in CFRD
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CFRD subjects had twice as many pulmonary exacerbations during the previous two years
as subjects with impaired (IGT) or normal (NGT) glucose tolerance (mean, 5.00 vs 2.27 and
2.59, SE = 0.56, p< 0.01). There was no difference in PEx admission length in CFRD, IGT or
NGT subjects (13.2, 11.2, 9.8, p = 0.14).
Given that CFRD subjects had more PEx but not increased SG, we next reviewed clinical
data to determine if glycemic control, as indicated by HbA1c, was associated with differences in
pulmonary health. We stratified subjects using the two-year mean HbA1c, defining stringent
control as HbA1c 6.5% and poor control as HbA1c> 6.5%. These two groups had no statisti-
cally significant differences in age, sex, or BMI, although subjects with poor control had been
diagnosed with CFRD for longer, as shown in Table 3.
Analysis of the entire study population revealed that those with a two-year average
HbA1c > 6.5% were admitted for 6 days longer than those with a two-year average
HbA1c  6.5% (mean: 16.1 vs 10.3, p <0.01, see Fig. 3) and scored lower measures of pulmo-
nary function, FEV1 (37 vs 67% predicted, p < 0.01) and on forced expiratory flow in the
middle 50% of the patient’s exhaled volume (FEF 25–75%, 14 vs 49% predicted, p < 0.01).
Within CFRD subjects, those with poor glycemic control had significantly reduced average
FEV1 and FEF25–75% scores. These findings suggest that glycemic control is correlated with
reduced morbidity (see Fig. 4). Duration of diabetes, while higher in CFRD patients with poor
glycemic control, was not directly correlated with PEx admission length or frequency or mean
FEV1 or FEF25–75%.
Discussion
We sought to determine if CFRD worsens health through an increase in SG, which could foster
bacterial growth and worsen pulmonary infections. However, our study found SG was highest
in subjects with NGT as compared to IGT or CFRD. Overall, SG concentration was usually
quite low in comparison with previously reported SG values in adult CF patients. CFRD sub-
jects had higher morbidity than CF subjects without diabetes and poor glycemic control was as-
sociated with longer PEx hospitalizations and worse pulmonary function.
Table 2. R2 and p-values from correlations between SG and clinical parameters.
Clinical parameter R2 (p value)
Age (years) 0.01 (0.99)
Sex (ANOVA) <0.01 (0.55)
Ethnicity (ANOVA) <0.01 (0.55)
BMI (kg/m2) <0.01 (0.94)
FEV1 (% predicted) <0.01 (0.65)
FEF 25–75% (% predicted) 0.09 (<0.01)
CFRD diagnosis (ANOVA) 0.09 <0.01
HbA1c (%)
mean (2012–2013) <0.01 (0.54)
at sputum collection 0.02 (0.34)
PEx status, at sputum
collection (ANOVA) 0.05 (0.07)
Total PEx (2012–2013) 0.01 (0.29)




PLOSONE | DOI:10.1371/journal.pone.0119938 March 24, 2015 5 / 10
Glucose in CF sputum was previously measured in just four samples from nonexacerbating
adults by Palmer et al. [15], reporting a mean concentration of 3.2 mM. This finding has been
widely used in synthetic CF sputum medium for in vitromodels of CF airways. While the
mean SG found here was similar to Palmer’s (4.8 vs 3.2 mM), our average is strongly skewed by
a few outlying high values. It is likely more physiologically relevant to describe SG by the medi-
an of 0.7 mM, or even 0 mM, as was often the case. Our results have the advantage of a much
larger sample size (117 vs 4) from pediatric and adult subjects, with the health records to put
these findings in context. The lack of relationship between increased SG and CFRD diagnosis
suggests the increased morbidity in CFRD is independent of SG.
The link between CFRD and worsening pulmonary function has been described previously.
CFRD subjects have shown a greater rate in decline of FEV1 than NGT subjects [3], with the
most rapid decline correlating with the lowest endogenous insulin production [16]. Sims et al
[17] also showed a significant decrease in lung function in female CFRD subjects when com-
pared to NGT controls. Despite the tendency for worse health outcomes once CFRD has been
diagnosed, it is encouraging that our results correlated lower HbA1c with shorter PEx and
Table 3. Clinical parameters of CFRD subjects.
Clinical parameter HbA1c > 6.5% HbA1c  6.5% p value
Male / Female, n 4 / 6 9 / 8
Ethnicity, n
White / Hispanic / Black and other 8 / 1 / 1 6 / 11 / 0
Age (years), mean (SD) 30.6 (11.9) 25.8 (10.8) 0.15
BMI (kg/m2), mean (SD) 22.5 (4.7) 21.6 (4.4) 0.33
CFRD duration (years), mean (SD) 15.3 (9.3) 6.1 (8.1) 0.01
Two-year mean HbA1c (%), mean (SD) 7.3 (0.5) 5.8 (0.4) <0.01
SG (mM), mean (SD) 0.70 (0.90) 1.7 (3.9) 0.18
PEx total, mean (SD) 4.6 (3.0) 5.3 (3.4) 0.31
PEx admission length (days), mean (SD) 15.1 (6.2) 11.9 (5.4) 0.10
FEV1 (% predicted), mean (SD) 40.4 (14.5) 58.4 (18.2) 0.03
FEF25–75% (% predicted), mean (SD) 15.2 (8.7) 36.5 (22.9) 0.01
doi:10.1371/journal.pone.0119938.t003
Fig 3. Glucose tolerance and two-year pulmonary exacerbation history.CFRD subjects had approximately twice as many pulmonary exacerbations as
subjects with impaired (IGT) or normal glucose tolerance (NGT, left panel). The average length of admission was not significantly different between these
groups (right panel). Diamonds are centered on each category’s mean and the vertical distance represents the 95% confidence interval.
doi:10.1371/journal.pone.0119938.g003
SputumGlucose in CFRD
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better pulmonary function. While HbA1c is impacted by many factors besides glycemic control
[18], this suggests subjects may be able to minimize the short-term pulmonary damage from
CFRD with management of blood glucose—in addition to reducing long-term microvascular
complications of CFRD [19]. However, patients and physicians must weigh the benefits of
tight glycemic control against the increased risk of hypoglycemia. It is also encouraging that
duration of diabetes, a factor completely beyond the control of subjects and their physicians,
was not directly correlated with more or longer PEx or worsening pulmonary function.
One possible mechanism of CFRD’s negative impact on pulmonary health is insulinopenia:
insulin is an anabolic hormone important in signaling tissue growth and repair [16] and acts
on airway epithelial and smooth muscle cells [20], so a shortage of insulin could contribute to
worsening pulmonary function in CFRD. One study supported this hypothesis by reversing the
decline in pulmonary function of CFRD subjects with one year of insulin therapy [21]. Alterna-
tively, Waugh et al. [22] has suggested that as CFRD indicates endocrine pancreatic insufficien-
cy, it may also mark exocrine pancreatic insufficiency and worse malabsorption. The resulting
undernutrition would limit nutritional resources and thus also the body’s ability to repair lung
tissue from chronic and acute infections.
The surprising correlation between higher SG and NGT is counterintuitive. We initially hy-
pothesized that higher serum glucose levels in CFRD would correspond to higher sputum glu-
cose levels; however, there was a trend in the opposite direction. Insulin has been shown to
modulate transporters’ activity in lung epithelial cells [20], and it is conceivable that increased
insulin (associated with NGT) triggers greater flux of glucose across the airway epithelium, re-
sulting in higher SG. Alternately, microorganisms in the CF lung may affect SG and overall
pulmonary function. Just as infection patterns elsewhere in the body are different for diabetics
than those with NGT, the lung microbiome may also be altered in the context of CFRD. For in-
stance, if CFRD subjects have higher levels of glucose-utilizing organisms, these pathogens
may take up glucose preferentially, leaving comparatively little glucose in the extracellular mi-
lieu of sputum. In the future, comparative microbiome community sequencing and transcrip-
tomic analyses could help test this hypothesis. However, one should note that the HbA1c range
in these subjects was relatively narrow (5.2–8.1%), and these findings may not apply to patients
with higher HbA1c levels.
Fig 4. Mean pulmonary function test results by glycemic control in CFRD. CFRD subjects with HbA1c> 6.5% had significantly reduced average scores
of forced expiratory volume in one second (FEV1, left panel) and forced expiratory flow in the 25–75% of the patient’s exhaled volume (FEF25–75%, right
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Certain limitations to our findings should be considered. First, we have more sputum sam-
ples from subjects who were more frequently in clinic and admitted to the hospital. Thus, our
samples may over-represent exacerbating conditions. For instance, only 48% (56/117) of the
sputum samples were from well subjects, although most of our subjects are well more often
than not. A second limitation is that the samples are not uniformly from a fasting state versus
specific post-prandial time point which could acutely affect SG levels and might account for
the few outlying high values. Lastly, sputum samples are subject to contamination from food or
drink residues in the oropharynx as the sputum was expectorated, which could artificially in-
crease the tested SG concentration.
To better describe the conditions that affect SG and determine its peak concentration, future
work could focus on patients with continuous glucose monitors, or collecting multiple samples
over the course of an oral glucose tolerance test, when a spike in blood glucose is induced and
carefully followed. Glucose concentration in nasal secretions and breath condensates follows
blood glucose on a similarly rapid time scale [10, 11, 23], but the dynamics of lower airway SG
are unknown. The potential for SG as a predictor of an oncoming PEx also remains untested.
Additionally, the interactions between CF lung flora and SG are unexplored. For example, how
do microorganisms contribute to or deplete SG, and what biological effects does SG have on
bacterial growth rates, pathogenicity, and antibiotic resistance?
In conclusion, this work has shown that SG is frequently very low in CF subjects, but may
increase dramatically for unknown reasons. The pathophysiology of how CFRD negatively im-
pacts pulmonary health is evidently more complicated than a simple change in SG; however,
lower HbA1c, which generally indicates better glycemic control, is associated with shorter PEx
admissions and better pulmonary function. Current recommendations suggest a treatment
goal of HbA1c 7% for CFRD patients to reduce long-term microvascular complications [19],
but a more stringent goal of HbA1c 6.5% may also reduce short-term pulmonary complica-
tions and improve lung function.
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